Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

X4 Pharmaceuticals (XFOR) FCF Margin (2018 - 2025)

X4 Pharmaceuticals' FCF Margin history spans 6 years, with the latest figure at 623.75% for Q4 2025.

  • For Q4 2025, FCF Margin rose 145581.0% year-over-year to 623.75%; the TTM value through Dec 2025 reached 245.26%, up 620175.0%, while the annual FY2025 figure was 245.26%, 488681.0% up from the prior year.
  • FCF Margin reached 623.75% in Q4 2025 per XFOR's latest filing, up from 1576.83% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 2391.43% in Q1 2023 to a low of 11373.71% in Q2 2024.
  • Average FCF Margin over 4 years is 1140.26%, with a median of 333.4% recorded in 2025.
  • Peak YoY movement for FCF Margin: soared 17336bps in 2023, then soared 985982bps in 2025.
  • A 4-year view of FCF Margin shows it stood at 1671.94% in 2022, then skyrocketed by 43bps to 2391.43% in 2023, then plummeted by -187bps to 2079.57% in 2024, then soared by 70bps to 623.75% in 2025.
  • Per Business Quant, the three most recent readings for XFOR's FCF Margin are 623.75% (Q4 2025), 1576.83% (Q3 2025), and 1513.89% (Q2 2025).